Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Conclusions and clinical perspectives
Date
10 Oct 2016Session
Biomarker strategies to improve the treatment of castration-resistant prostate cancerPresenters
Felix FengAuthors
F. FengAuthor affiliations
- Radiation Oncology, University of Michigan, 48109-5010 - Ann Arbor/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: David Olmos
Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Resources:
Webcast
Translating the genomics landscape into clinical practice
Presenter: Rob Bristow
Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Resources:
Slides
Webcast
What is the role of CTCs?
Presenter: Howard Scher
Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Resources:
Slides
Webcast
Using circulating tumour DNA studies to improve the management of prostate cancer patients
Presenter: Gerhardt Attard
Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.